Polycystic ovary syndrome (PCOS) is the most common endocrinopathy that affects women. PCOS is also a leading cause of infertility. Women with PCOS may present with obesity, amenorrhea ...

HealthDay News — Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers, according to a study ...

A new study in Nature shows that when pregnant mice don’t have enough iron, their (usually male) fetuses with a Y sex ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

Moskov et al. explored over 5400 blood protein biomarkers in relation to separating malign from benign ovarian tumours in two cohorts of symptomatic women. The study detected and validated many ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

The 52mg LNG intra-uterine system (such as Mirena) has demonstrated the greatest long-term efficacy in reducing heavy ...

Between 2012 and 2022, incidence rates of breast cancer increased by 1% per year in women older than 50 years and by 1.4% in women younger than 50 years.